Xconomy Boston’s Top Stories of Q2 2014: Editor’s Picks

Here are my picks for our top local stories of the past quarter (April-June), and why.

Not a ranked list, just in reverse chronological order:

1. MA Warns Ride-Sharing, Car-Sharing Drivers of Insurance Risks

Could something as boring as insurance derail Uber?

2. Katrine Bosley, Former Avila CEO, Takes Helm at Editas

Cutting-edge genomics company, meet veteran exec.

3. The Series A Story in Boston Tech: $270M Invested in Past Year

Series A crunch? Not so much, if you read this list of deals.

4a. Zafgen Hauls In $96M in Upsized IPO

4b. Gelesis Resurfaces With $12M, Preps First Weight Loss Data

Obesity and weight loss continues to be a huge market for drugmakers.

6. Moderna, Changing Its Identity, Plots Army of mRNA Spinouts

One of the biggest biotech startups, now doing its own startups.

7. Lou Tartaglia Leaves Third Rock to Run High-Drama RNAi Startup

Attempted murder, shootings, bankruptcy… not your average VC/startup story.

8. Blackboard CEO Jay Bhatt on the Global Future of Edtech

Education tech hasn’t exploded yet, but it’s about to.

9. Five Lessons for Consumer Tech Startups in Springpad Shutdown

This one resonated with entrepreneurs, Springpad users, and anyone interested in why startups fail.

10. This Boston Lawyer Could Be Uber’s Nemesis As It Eyes Expansion

Everyone loves Uber. Everyone except her.

11. Facebook Boston Looks to Build Tech for the “Next Few Billion Users”

What’s the social network working on locally? Hard tech problems, not surprisingly.

12. Amazon Expands Boston-Area Office, Room for About 800

A scoop on the Internet retail giant’s plans in Kendall Square.

13. Greentown Startups Work Around VCs, Find Niches in Cleantech

Cleantech is on the rise—and here’s one of the hotspots around town.

14. How a Kidney Drug Almost Torpedoed Concert Pharma’s IPO

Near-death company stories are riveting, especially when the company is trying to go public.

15. Alkermes CEO Richard Pops on Building Big, Playing Well With Pharma

In-depth Q&A with one of biotech’s leading figures.

16. Non-Compete Debate Exposes Political Rift in Boston Tech Industry

Pretty much boils down to VCs and startups vs. EMC.

17. Doctors Going Mobile, But Still Skeptical of Connected Health

Why? Cost and technology problems. Also physician culture and patient privacy.

18. Agios’s Blood Cancer Drug Shines in First Clinical Test

Very early but promising results for an experimental cancer treatment.

19. The Big Patent Lawsuit Settlement Memo You’re Not Supposed to See

Boston University went and sued Apple, Amazon, and a bunch of tech companies. Here’s how they settled.

20. Backed by Billionaire, Berg Pharma Aims to Speed Drugmaking

Brash biotech looking to revolutionize healthcare. We’ll see.

Author: Gregory T. Huang

Greg is a veteran journalist who has covered a wide range of science, technology, and business. As former editor in chief, he overaw daily news, features, and events across Xconomy's national network. Before joining Xconomy, he was a features editor at New Scientist magazine, where he edited and wrote articles on physics, technology, and neuroscience. Previously he was senior writer at Technology Review, where he reported on emerging technologies, R&D, and advances in computing, robotics, and applied physics. His writing has also appeared in Wired, Nature, and The Atlantic Monthly’s website. He was named a New York Times professional fellow in 2003. Greg is the co-author of Guanxi (Simon & Schuster, 2006), about Microsoft in China and the global competition for talent and technology. Before becoming a journalist, he did research at MIT’s Artificial Intelligence Lab. He has published 20 papers in scientific journals and conferences and spoken on innovation at Adobe, Amazon, eBay, Google, HP, Microsoft, Yahoo, and other organizations. He has a Master’s and Ph.D. in electrical engineering and computer science from MIT, and a B.S. in electrical engineering from the University of Illinois, Urbana-Champaign.